Chinese Stem Cell Therapy Restores Heart Function in 90% of Phase 2 Patients

3 articles · Updated · South China Morning Post · Aug 20

Nanjing Drum Tower Hospital said long-term follow-up from a phase 2 trial showed 90% of severe heart-failure patients regained heart function after the therapy.
The study, published in Nature Medicine, found patients injected with iPSC-derived heart muscle cells after bypass surgery outperformed a control group on cardiac function tests.
The treatment targets severe heart failure, a condition that can leave patients breathless after a few steps, unable to lie flat at night and frequently hospitalized.
The results mark a notable clinical milestone for regenerative heart therapy in China, though the report did not detail patient counts or next-stage trial timing.

Sources

South China Morning Post18h ago

Chinese Stem Cell Therapy Restores Heart Function in 90% of Patients in Phase 2 Trial

Yahoo Singapore News2h ago

Chinese stem cell therapy reverses heart failure in 90% of patients, landmark trial finds - Yahoo News Singapore

X3h ago

Chinese researchers reverse heart failure in 90% of patients. The long-term results of a phase 2 clinical study were published in the journal Nature Medicine. This technology can reprogram damaged hearts to

4 Sources

With 90% showing improvement, will allogeneic stem cell therapies cure end-stage heart disease before manufacturing bottlenecks halt their progress?

Can scientists overcome the dangerous rhythm disruptions triggered by new electrically active heart cells injected into failing human hearts?

The 2026 Cardiac Regeneration Breakthrough: iPSC Therapies, Regulatory Milestones, and the Future of Heart Failure Care

Overview

When a heart attack destroys billions of heart muscle cells, the heart forms rigid scar tissue that leads to heart failure, and options like transplants are limited by donor shortages. Scientists are now using induced pluripotent stem cells (iPSCs) to create new heart cells, but these donor-derived cells can trigger immune rejection, requiring strong immunosuppressive drugs that cause serious side effects. To solve this, researchers use gene editing to remove immune markers from iPSCs and add protective factors, aiming to shield the new cells from both T cells and natural killer cells, potentially eliminating the need for immunosuppression and making regenerative heart therapy safer and more accessible.

...